ArticleCritical care (London, England)2013
CD8⁺ T-cell counts: an early predictor of risk and mortality in critically ill immunocompromised patients with invasive pulmonary aspergillosis.
Article in Critical care (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Effects of postoperative antifungal therapy on the recurrence of Aspergillus infection after pulmonary aspergilloma resection: a prospective, randomized, controlled, single-center, 24-month, open-label, parallel group trial.BMC infectious diseases · 2025Trial
- Transcriptomic and proteomic profiling of pulmonary mucormycosis reveals a failed activation of host immune response.Frontiers in immunology · 2026Article
- Immunogenicity and efficacy of CNA25 as a potential whole-cell vaccine against systemic candidiasis.EMBO molecular medicine · 2024Article
- Peripheral Blood CD8+T Cell as a Prognostic Biomarker for Hospitalised COVID-19 Patients Without Antiviral Treatment.Infection and drug resistance · 2024Article
- The pathogenic and clinical characteristics of severe fever with thrombocytopenia syndrome patients with co-infections.Frontiers in cellular and infection microbiology · 2023Article
- Innate and Adaptive Immune Responses Induced by Aspergillus fumigatus Conidia and Hyphae.Current microbiology · 2022Article
- T-lymphocyte subtyping: an early warning and a potential prognostic indicator of active cytomegalovirus infection in patients with sepsis.Immunology and cell biology · 2022Article
- COVID-Associated Pulmonary Aspergillosis and Its Related Outcomes: A Single-Center Prospective Observational Study.Cureus · 2021Article
- Early-Warning Immune Predictors for Invasive Pulmonary Aspergillosis in Severe Patients With Severe Fever With Thrombocytopenia Syndrome.Frontiers in immunology · 2021Article
- mTOR Modulates CD8+ T Cell Differentiation in Mice with Invasive Pulmonary Aspergillosis.Open life sciences · 2018Article
- Preparations for Invasion: Modulation of Host Lung Immunity During PulmonaryFrontiers in immunology · 2018Review
- Role of Triggering Receptor Expressed on Myeloid Cell-1 Expression in Mammalian Target of Rapamycin Modulation of CD8Chinese medical journal · 2017Article
- Methods of Controlling Invasive Fungal Infections Using CD8Frontiers in immunology · 2017Review
- IL-12 Influence mTOR to Modulate CD8International journal of medical sciences · 2017Article
- mTOR Modulates Lymphocyte Differentiation through T-bet and Eomesodermin in Response to Invasive Pulmonary Aspergillosis in Rats.Chinese medical journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCritically ill immunocompromised (CIIC) patients with pulmonary infection are a population at high risk for invasive pulmonary aspergillosis (IPA). The host defenses are important factors to consider in determining the risk and outcome of infection. Quantification of changes in the status of host immunity could be valuable for clinical diagnosis and outcome prediction.
methodsWe evaluated the quantitative changes in key humoral and cellular parameters in CIIC patients with pulmonary infection and their potential influence on the risk and prognosis of IPA. We monitored the evolution of these parameters in 150 CIIC patients with pulmonary infection on days 1, 3 and 10 (D1, D3 and D10) following ICU admission. The primary outcome was 28-day mortality. Follow-up included 60- and 90-day mortality.
resultsAmong the 150 CIIC patients included in this study, 62 (41.3%) had microbiological evidence of IPA. Compared with patients without IPA, CD3⁺, CD8⁺, CD28⁺CD4⁺ and CD28⁺CD8⁺ CD28⁺CD8⁺ T-cell counts (D1, D3 and D10) and B-cell counts (D1 and D3) were significantly reduced in patients with IPA (P < 0.05). Multivariate regression analysis revealed that CD8⁺ (D3 and D10) (odds ratio (OR) 0.34, 95% confidence interval (CI) 0.23 to 0.46; OR 0.68, 95% CI 0.56 to 0.80), CD28⁺CD8⁺ (D3) (OR 0.73, 95% CI 0.61 to 0.86) and CD3⁺ (D10) (OR 0.81, 95% CI 0.63 to 0.98) T-cell counts were independent predictors of IPA in CIIC patients. Receiver operating characteristic analysis of immune parameters predicting 28-day mortality revealed area under the curve values of 0.82 (95% CI 0.71 to 0.92), 0.94 (95% CI 0.87 to 0.99), and 0.94 (95% CI 0.85 to 0.99) for CD8⁺ T-cell counts (D1, D3 and D10, respectively) and 0.84 (95% CI 0.75 to 0.94), 0.92 (95% CI 0.85 to 0.99) and 0.90 (95% CI 0.79 to 0.99) for CD28⁺CD8⁺ T-cell counts (D1, D3 and D10, respectively). Kaplan-Meier survival analysis provided evidence that CD8⁺ and CD28⁺CD8⁺ T-cell counts (<149.5 cells/mm³ and <75 cells/mm³, respectively) were associated with early mortality in CIIC patients with IPA (logrank test; P < 0.001).
conclusionsCD8⁺ and CD28⁺CD8⁺ T-cell counts were significantly lower in CIIC patients with IPA than in non-IPA patients. Lower CD8⁺ and CD28⁺CD8⁺ T-cell counts in CIIC patients with pulmonary infection were associated with higher risk and early mortality in IPA and may be valuable for clinical diagnosis and outcome prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.